HHS and CDC Recommendations to Expand the Use of Naloxone—A Life-saving, yet Underutilized Drug for Reversing Opioid Overdose

COCA Call September 17, 2019

Image of Continuing Education Credits abbreviation. = Free Continuing Education

Date: Tuesday, September 17,  2019

Time: 2:00pm-3:00pm (Eastern Time)

Instructions for Obtaining Continuing Education (CE)
To receive continuing education (CE) for WC2922-091719 – (Webcast) Clinician Outreach and Communication Activity (COCA) Calls/Webinars – COCA Call: HHS and CDC Recommendations to Expand the Use of Naloxone—A Life-saving, yet Underutilized Drug for Reversing Opioid Overdose, September 17, 2019, please visit TCEO and follow these 9 Simple Steps by October 21, 2019

To receive continuing education (CE) for WD2922-091719 – Clinician Outreach and Communication Activity (COCA) Calls/Webinars – COCA Call: HHS and CDC Recommendations to Expand the Use of Naloxone—A Life-saving, yet Underutilized Drug for Reversing Opioid Overdose, September 17, 2019 (Web on Demand), please visit TCEO and follow these 9 Simple Steps by October 22, 2021.

Overview

About 48,000 drug overdose deaths involved opioids in the United States in 2017. Naloxone is a life-saving drug that can reverse the effects of an opioid overdose. Despite recent progress in naloxone dispensing, naloxone remains under-prescribed and underused, often in a variable pattern. Healthcare providers and pharmacists play a critical role in ensuring patients receive naloxone, as they have a frontline view and can make progress in prescribing and dispensing of naloxone. The 2016 CDC Guideline for Prescribing Opioids for Chronic Pain recommends that healthcare providers consider prescribing or dispensing naloxone to patients at risk for overdose.

During this COCA Call, clinicians will learn about HHS and CDC recommendations for the prescribing or dispensing of naloxone to patients at risk for opioid overdose.

At the conclusion of the session, the participant will be able to accomplish the following:

  1. Cite background information on the topic covered during the presentation.
  2. Discuss CDC’s role in the topic covered during the presentation.
  3. Describe the topic’s implications for clinicians.
  4. Discuss concerns and/or issues related to preparedness for and/or response to urgent public health threats.
  5. Promote health improvement, wellness, and disease prevention in cooperation with patients, communities, at-risk populations, and other members of an interprofessional team of health care providers.

 

Activity Specific Objectives

At the conclusion of the session, the participant will be able to accomplish the following:

  1. Identify the risk factors for opioid overdose.
  2. Promote the CDC Guideline recommendations and the Department of Health and Human Services (HHS) guidance on naloxone co-prescribing.
  3. Describe the history of naloxone use and current state-level policies.
  4. Discuss the steps that can be taken to link survivors of opioid overdose to treatment.
  5. Describe actions that can help expand naloxone access at the local level.

Vice Admiral Jerome M. Adams, MD, MPH (USPHS)
20th U.S. Surgeon General

Captain Christopher M. Jones, PharmD, DrPH, MPH (USPHS)
Director, Strategy and Innovation, CDC Injury Center
National Center for Injury Prevention and Control
Centers for Disease Control and Prevention

A few minutes before the webinar starts, please click the link below to join:

https://zoom.us/j/996942494external icon

Or iPhone one-tap :
US: +16468769923,,996942494#  or +16699006833,,996942494#

Or Telephone:
Dial(for higher quality, dial a number based on your current location):
US: +1 646 876 9923  or +1 669 900 6833

Webinar ID: 996 942 494
International numbers available: https://zoom.us/u/anixAVglVexternal icon

Life-Saving Naloxone from Pharmacies Vital Signs Report: https://www.cdc.gov/vitalsigns/naloxone/index.html

Accreditation Statements

CME: The Centers for Disease Control and Prevention is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.

The Centers for Disease Control and Prevention designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CNE: The Centers for Disease Control and Prevention is accredited as a provider of Continuing Nursing Education by the American Nurses Credentialing Center’s Commission on Accreditation.

This activity provides 1.0 contact hour.

CEU: The Centers for Disease Control and Prevention is authorized by IACET to offer 0.1 CEU’s for this program.

CECH: Sponsored by the Centers for Disease Control and Prevention, a designated provider of continuing education contact hours (CECH) in health education by the National Commission for Health Education Credentialing, Inc. This program is designated for Certified Health Education Specialists (CHES) and/or Master Certified Health Education Specialists (MCHES) to receive up to total 1 Category I continuing education contact hours. Maximum advanced level continuing education contact hours available are 0. CDC provider number 98614.

Image of acpe logo.CPE: The Centers for Disease Control and Prevention is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

This program is a designated event for pharmacists to receive) 0.1 CEUs in pharmacy education. The Universal Activity Number is 0387-0000-19-158-H04P and JA4008229-0000-20-108-H01-P.

This activity has been designated as Knowledge-Based.

Once credit is claimed, an unofficial statement of credit is immediately available on TCEOnline. Official credit will be uploaded within 60 days on the NABP/CPE Monitor.

For Certified Public Health Professionals (CPH)

The Centers for Disease Control and Prevention is a pre-approved provider of Certified in Public Health (CPH) recertification credits and is authorized to offer 1 CPH recertification credit for this program.

AAVSB/RACE: This program was reviewed and approved by the AAVSB RACE program for 1.0 hours of continuing education. Participants should be aware that some boards have limitations on the number of hours accepted in certain categories and/or restrictions on certain methods of delivery of continuing education. Please contact the AAVSB RACE program if you have any comments/concerns regarding this program’s validity or relevancy to the veterinary profession.

DISCLOSURE: In compliance with continuing education requirements, CDC, our planners, our presenters, and their spouses/partners wish to disclose they have no financial interests or other relationships with the manufacturers of commercial products, suppliers of commercial services, or commercial supporters. Planners have reviewed content to ensure there is no bias.

CDC did not accept commercial support for this continuing education activity.

Page last reviewed: April 1, 2019